ABSTRACT
The Human Immunodeficiency Virus (HIV) is one of the most common chronic infectious diseases of humans. Increasing the expected lifetime of the patients depends on the use of optimal antiretroviral therapies. The emergence of the drug-resistant strains may decrease the effects of treatments and lead to Acquired Immune Deficiency Syndrome (AIDS) even if the existence of antiretroviral therapy. Investigation of the genotype-phenotype relations is a crucial process to optimize the therapy protocols of the patients. Here we propose a mathematical modelling framework to address the effect of initial strains, initiation timing and adherence levels of nucleotide reverse transcriptase inhibitors (NRTI) on the emergence of a possible AIDS phase. For the first time, we have combined the existing Stanford HIV drug resistance data with a multi-strain within-host ordinary differential equation (ODE) model to track the dynamics of most common NRTI resistant strains. Regardless of the drug choice, the late initiation and poor adherence levels to the NRTI therapy increase the probability of the emergence of the AIDS phase. Overall, the 3TC, D4T-AZT and TDF-D4T drug combinations provide higher success rates. The results are in line with genotype-phenotype data and pharmacokinetic parameters of the NRTI inhibitors, but we show the heavy influence of neighbour viral strains of the initial ones has a considerable effect on the success/failure rates. Improving multiscale models can contribute to understanding the disease progression and treatment options.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by TUBITAK, 2232 -International Fellowship for Outstanding Researchers, Project number 118C244. All the results are in sole responsibility of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos